Document is current
Any future updates will be listed below
-
Authors
Vetter, Valentin Max https://orcid.org/0000-0001-5003-7766
Demircan, Kamil
Homann, Jan
Chillon, Thilo Samson
Mülleder, Michael
Shomroni, Orr
Steinhagen-Thiessen, Elisabeth
Ralser, Markus
Lill, Christina M.
Bertram, Lars
Schomburg, Lutz
Demuth, Ilja https://orcid.org/0000-0002-4340-2523
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (16LW0239K, 01EP2201, #01UW0808; #16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01GL1716A, and #01GL1716B)
Berlin University Alliance (BUA Link Lab, 501_Massenspektrometrie, 501_Linklab)
Deutschen Konsortium für Translationale Krebsforschung (BE01 1020000483)
Deutsche Forschungsgemeinschaft (LI 2654/4-1, 460683900, CRC/TR 296 “LocoTact”, 460683900)
European Research Council (Lifebrain)
Cure Alzheimer's Fund (“CIR-CUITS” consortium)
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 22 March 2025
First Online: 25 April 2025
Declarations
:
: All participants gave written informed consent. The Ethics Committee of the Charité – Universitätsmedizin Berlin approved the study (approval numbers EA2/029/09 and EA2/144/16). The study was conducted in accordance with the Declaration of Helsinki and was registered in the German Clinical Trials Registry as DRKS00009277.
: LS holds shares of selenOmed GmbH, a company involved in Se status assessment; no other relationships or activities that could appear to have influenced the submitted work are indicated. Other authors: none.
